Allarity Therapeutics (ALLR) vs NewcelX (NCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Allarity Therapeutics (ALLR) has outperformed NewcelX (NCEL) over the past year, losing 42.2% versus a loss of 83.3%. NewcelX is the larger company by market cap ($18.0 million vs $15.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | NCEL |
|---|---|---|
| Share price | $0.9819 | $3.11 |
| Market cap | $15.62M | $17.96M |
| 1-day change | -0.21% | +2.47% |
| YTD return | -9.08% | +63.68% |
| 1-year return | -42.24% | -83.32% |
| 5-year return | — | -99.68% |
| P/E ratio (TTM) | — | 5.98 |
| EPS (TTM) | $-0.79 | $0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.84 | $18.60 |
| 52-week low | $0.769 | $1.83 |
| Distance from 52-week high | -46.64% | -83.28% |
| Analyst consensus | none | none |
| Avg. price target upside | +1020.28% | +639.55% |
| Average volume | 90.75K | 10.28K |
| Shares outstanding | 15.91M | 5.78M |
| Employees | 7 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLR has outperformed NCEL by 41.1 percentage points over the past year.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
ALLR vs NCEL FAQ
Which is bigger, Allarity Therapeutics or NewcelX?
NewcelX (NCEL) is larger, with a market capitalization of $17.96M compared with $15.62M for Allarity Therapeutics (ALLR).
Which stock has performed better over the past year, ALLR or NCEL?
ALLR returned -42.24% over the past 12 months, compared with -83.32% for NCEL (price return, excluding dividends). Past performance does not predict future results.
Are Allarity Therapeutics and NewcelX in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.